Blackstone Life Sciences
Blackstone Life Sciences (BXLS) is a private investment platform within Blackstone that invests across the life cycle of life-science companies and products, collaborating with pharmaceutical, biotechnology, and medical-technology firms to fund clinical trials and advance products to market. It was established in 2018 following Blackstone's acquisition of Clarus Ventures.
40% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-c (60% of deals). Average disclosed round size is $140.4M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
$6.3B
Top Stage
Series C
Last 12 Mo
0
Team
Reginald (“Reg”) J. Brown
Partner, Kirkland & Ellis
William G. Parrett
Retired CEO and Senior Partner, Deloitte (Deloitte Touche Tohmatsu)
Jasvinder Khaira
Global Head of Blackstone N1 and Blackstone Growth
Kenneth Caplan
Global Co-Chief Investment Officer
Lionel Assant
Global Co-Chief Investment Officer
Ruth Porat
President & Chief Investment Officer, Alphabet and Google
Christine Anderson
Global Head of Corporate Affairs
Christopher James
Global Head of Tactical Opportunities
Gilles Dellaert
Global Head of Blackstone Credit & Insurance
James W. Breyer
Founder and CEO of Breyer Capital
Joan Solotar
Global Head of Blackstone Private Wealth
Portfolio Breakdown
Stage Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Avencell | Series B | $112M | Oct 2024 |
 Praxis Precision Medicines | Series C | $110M | Jul 2020 |
 Imago Biosciences | Series C | $80M | — |
| AAnnexon | Series C | $100M | — |
| UUniquity Bio | Unknown | $300M | — |
Top Co-Investors
Last updated: 14 September 2026